Netherlands-based biopharmaceutical company Argenx reported a significant surge in third-quarter sales, driven primarily by robust demand for its flagship drug, VYVGART. The strong performance underscores growing market confidence in the company’s innovative autoimmune therapy and marks a pivotal milestone in Argenx’s commercial expansion. Investors responded positively, with the company’s stock gaining momentum on TradingView following the impressive quarterly results.
Netherlands Argenx Reports Significant Q3 Sales Growth Driven by VYVGART Demand
Argenx, the Netherlands-based biotechnology firm, reported a robust surge in its third-quarter sales, largely fueled by the escalating demand for its flagship therapy, VYVGART. The company’s revenue growth exceeded market expectations as VYVGART continued to gain traction among physicians and patients, reaffirming its position in treating neuromuscular diseases. This uptick signals not only successful…
—-
Author : Isabella Rossi
Publish date : 2026-10-23 05:08:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
